KR20120127495A - 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체 - Google Patents

8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체 Download PDF

Info

Publication number
KR20120127495A
KR20120127495A KR1020127023813A KR20127023813A KR20120127495A KR 20120127495 A KR20120127495 A KR 20120127495A KR 1020127023813 A KR1020127023813 A KR 1020127023813A KR 20127023813 A KR20127023813 A KR 20127023813A KR 20120127495 A KR20120127495 A KR 20120127495A
Authority
KR
South Korea
Prior art keywords
salt
polymorph
campylate
compound
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127023813A
Other languages
English (en)
Korean (ko)
Inventor
페트리시아 안 바스포드
앤서니 마이클 캠페타
아담 길모어
매튜 카메론 존스
엘레페리오스 고굴로스
수만 루스라
로버트 왈튼
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43859823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120127495(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20120127495A publication Critical patent/KR20120127495A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020127023813A 2010-02-12 2011-02-10 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체 Ceased KR20120127495A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30427710P 2010-02-12 2010-02-12
US61/304,277 2010-02-12
PCT/IB2011/050571 WO2011098971A1 (en) 2010-02-12 2011-02-10 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005968A Division KR102108226B1 (ko) 2010-02-12 2011-02-10 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체

Publications (1)

Publication Number Publication Date
KR20120127495A true KR20120127495A (ko) 2012-11-21

Family

ID=43859823

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127023813A Ceased KR20120127495A (ko) 2010-02-12 2011-02-10 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체
KR1020197005968A Active KR102108226B1 (ko) 2010-02-12 2011-02-10 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197005968A Active KR102108226B1 (ko) 2010-02-12 2011-02-10 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체

Country Status (32)

Country Link
US (5) US8754072B2 (cg-RX-API-DMAC10.html)
EP (4) EP3150610B1 (cg-RX-API-DMAC10.html)
JP (6) JP5745283B2 (cg-RX-API-DMAC10.html)
KR (2) KR20120127495A (cg-RX-API-DMAC10.html)
CN (2) CN102884066B (cg-RX-API-DMAC10.html)
AR (2) AR080164A1 (cg-RX-API-DMAC10.html)
AU (1) AU2011213944B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012019050B1 (cg-RX-API-DMAC10.html)
CA (2) CA3024216C (cg-RX-API-DMAC10.html)
CY (3) CY1118319T1 (cg-RX-API-DMAC10.html)
DK (2) DK2534153T4 (cg-RX-API-DMAC10.html)
ES (2) ES2607806T5 (cg-RX-API-DMAC10.html)
FI (2) FI2534153T4 (cg-RX-API-DMAC10.html)
FR (1) FR18C1049I2 (cg-RX-API-DMAC10.html)
HR (2) HRP20161742T4 (cg-RX-API-DMAC10.html)
HU (3) HUE030969T4 (cg-RX-API-DMAC10.html)
IL (1) IL220921B (cg-RX-API-DMAC10.html)
LT (3) LT3150610T (cg-RX-API-DMAC10.html)
LU (1) LUC00093I2 (cg-RX-API-DMAC10.html)
MX (1) MX343383B (cg-RX-API-DMAC10.html)
NL (1) NL300958I2 (cg-RX-API-DMAC10.html)
NO (1) NO2018039I1 (cg-RX-API-DMAC10.html)
NZ (1) NZ601445A (cg-RX-API-DMAC10.html)
PL (2) PL2534153T5 (cg-RX-API-DMAC10.html)
PT (2) PT2534153T (cg-RX-API-DMAC10.html)
RS (2) RS59494B1 (cg-RX-API-DMAC10.html)
RU (1) RU2570198C2 (cg-RX-API-DMAC10.html)
SG (2) SG10201406805RA (cg-RX-API-DMAC10.html)
SI (2) SI2534153T2 (cg-RX-API-DMAC10.html)
SM (3) SMT201900634T1 (cg-RX-API-DMAC10.html)
TW (1) TWI545123B (cg-RX-API-DMAC10.html)
WO (1) WO2011098971A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607806T5 (es) 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
TW201516636A (zh) * 2013-10-22 2015-05-01 鴻海精密工業股份有限公司 電子裝置及其供電方法
KR20170043597A (ko) * 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
US20190276405A1 (en) * 2016-05-16 2019-09-12 Pulmagen Therapeutics (Asthma) Limited Crystal of quinoline derivative
DE102016218772A1 (de) * 2016-09-28 2018-03-29 Bruker Biospin Gmbh Verbesserte Temperierung eines NMR-MAS-Rotors
EP3573990B1 (en) * 2017-01-24 2024-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
JP2021501771A (ja) * 2017-11-03 2021-01-21 サンド・アクチエンゲゼルシヤフト 三環系ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤の結晶性塩
WO2019115000A1 (en) * 2017-12-15 2019-06-20 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
WO2019207498A1 (en) * 2018-04-25 2019-10-31 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
CN111217818A (zh) * 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
US12503467B2 (en) 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
CN111004244A (zh) * 2019-12-27 2020-04-14 重庆市碚圣医药科技股份有限公司 一种瑞卡帕布樟脑磺酸盐的合成方法
WO2021156140A1 (en) 2020-02-03 2021-08-12 Sandoz Ag Polymorph of rucaparib mesylate
PE20221838A1 (es) * 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
CN116113406B (zh) 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
ES3051838T3 (en) 2020-07-14 2025-12-30 Assia Chem Ind Ltd Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
PE20231656A1 (es) * 2020-11-02 2023-10-17 Trethera Corp Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023152754A1 (en) * 2022-02-08 2023-08-17 Sawant, Mohit Manikrao Crystalline form of rosuvastatin allyl ester
AU2022489881A1 (en) * 2022-11-30 2025-06-19 Ideaya Biosciences, Inc. 2-oxoquinazoline crystalline forms
WO2026053244A1 (en) * 2024-09-07 2026-03-12 Council Of Scientific & Industrial Research Phosphorus-containing rucaparib as parp inhibitor

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489011A (en) 1983-05-16 1984-12-18 Merrell Dow Pharmaceuticals Inc. Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US5835420A (en) 1997-06-27 1998-11-10 Aplus Flash Technology, Inc. Node-precise voltage regulation for a MOS memory system
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
KR100452491B1 (ko) 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
KR20040011751A (ko) 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
EP1575936A1 (en) † 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
CA2581025C (en) * 2004-09-22 2011-06-07 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CA2580833C (en) * 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
CN101384264B (zh) * 2004-09-22 2012-03-14 辉瑞大药厂 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
KR100843401B1 (ko) 2006-12-04 2008-07-04 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법
CN103951583B (zh) * 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
EP2065385A1 (en) † 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
JP2011506315A (ja) * 2007-12-05 2011-03-03 バイアル−ポルテラ アンド シーエー，エス．エー． 新たな塩、及び結晶形
KR20090060674A (ko) 2007-12-10 2009-06-15 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
EP2240466B1 (en) † 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US8393431B2 (en) 2009-01-17 2013-03-12 Boomerang Systems, Inc. Omnidirectional drive and steering unit
ES2607806T5 (es) 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
CN107767647A (zh) 2011-09-23 2018-03-06 金泰克斯公司 用于后视镜显示的系统和方法
US9221946B2 (en) 2011-12-26 2015-12-29 Wintech Polymer Ltd. Polybutylene terephthalate resin pellets, and production method for said polybutylene terephthalate resin pellets
US9384339B2 (en) 2012-01-13 2016-07-05 Telecommunication Systems, Inc. Authenticating cloud computing enabling secure services
US10181126B2 (en) 2012-03-13 2019-01-15 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
KR101984831B1 (ko) 2013-01-31 2019-05-31 삼성전자 주식회사 반도체 패키지 및 그 제조 방법
CN103309115B (zh) 2013-05-30 2016-03-23 京东方科技集团股份有限公司 彩色电泳显示面板及其制造方法、显示装置
US9501163B2 (en) 2014-05-06 2016-11-22 Symbol Technologies, Llc Apparatus and method for activating a trigger mechanism
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
EP2534153B1 (en) 2016-09-21
NO2018039I1 (no) 2018-11-15
US8754072B2 (en) 2014-06-17
US20120302550A1 (en) 2012-11-29
US20180092925A1 (en) 2018-04-05
JP2018199679A (ja) 2018-12-20
SG182533A1 (en) 2012-08-30
US20150238504A1 (en) 2015-08-27
HUE047248T2 (hu) 2020-04-28
LT3150610T (lt) 2019-11-11
AU2011213944A1 (en) 2012-08-09
CA2787881C (en) 2019-01-08
AU2011213944B2 (en) 2014-10-02
CY1122218T1 (el) 2020-11-25
ES2607806T3 (es) 2017-04-04
AR080164A1 (es) 2012-03-21
SI2534153T1 (sl) 2017-01-31
RS55487B1 (sr) 2017-04-28
HUE030969T4 (hu) 2024-11-28
DK3150610T3 (da) 2019-11-04
US20200000821A1 (en) 2020-01-02
LUC00093I1 (cg-RX-API-DMAC10.html) 2018-11-15
JP6640931B2 (ja) 2020-02-05
RS59494B1 (sr) 2019-12-31
IL220921B (en) 2020-03-31
BR112012019050A2 (pt) 2016-09-13
RS55487B2 (sr) 2024-06-28
FR18C1049I1 (fr) 2019-02-15
LTC2534153I2 (lt) 2021-03-10
PL3150610T3 (pl) 2020-02-28
EP4166558A1 (en) 2023-04-19
JP2015131858A (ja) 2015-07-23
HRP20161742T1 (hr) 2017-02-24
HRP20161742T4 (hr) 2024-07-05
US9045487B2 (en) 2015-06-02
LT2534153T (lt) 2016-12-12
JP2011168587A (ja) 2011-09-01
FI2534153T4 (fi) 2024-06-26
KR102108226B1 (ko) 2020-05-08
HUE030969T2 (en) 2017-06-28
HRP20191944T1 (hr) 2020-01-24
ES2607806T5 (es) 2024-10-07
MX343383B (es) 2016-11-03
PT3150610T (pt) 2019-11-11
ES2753748T3 (es) 2020-04-14
KR20190026043A (ko) 2019-03-12
FIC20180039I1 (fi) 2018-11-16
AR109356A2 (es) 2018-11-21
CN102884066A (zh) 2013-01-16
SMT201600462T1 (it) 2017-03-08
TWI545123B (zh) 2016-08-11
JP2016216507A (ja) 2016-12-22
BR112012019050A8 (pt) 2017-12-26
SI3150610T1 (sl) 2019-12-31
CY1118319T1 (el) 2017-06-28
DK2534153T4 (da) 2024-06-03
CA3024216C (en) 2021-03-30
US9861638B2 (en) 2018-01-09
SMT201600462B (it) 2017-03-08
DK2534153T3 (en) 2017-01-09
EP3150610B1 (en) 2019-07-31
BR112012019050B1 (pt) 2021-12-21
PL2534153T5 (pl) 2024-11-18
JP2021107460A (ja) 2021-07-29
PT2534153T (pt) 2016-12-27
CA2787881A1 (en) 2011-08-18
EP3597651A1 (en) 2020-01-22
CN104876937A (zh) 2015-09-02
HK1176617A1 (zh) 2013-08-02
JP5745283B2 (ja) 2015-07-08
CN102884066B (zh) 2015-01-07
NZ601445A (en) 2014-08-29
MX2012008911A (es) 2012-08-15
PL2534153T3 (pl) 2017-08-31
SG10201406805RA (en) 2014-11-27
JP2020050671A (ja) 2020-04-02
NL300958I2 (nl) 2018-12-19
EP2534153B2 (en) 2024-05-22
WO2011098971A1 (en) 2011-08-18
LUC00093I2 (cg-RX-API-DMAC10.html) 2019-12-24
HUS1800046I1 (hu) 2018-12-28
CY2018031I2 (el) 2019-11-27
TW201144316A (en) 2011-12-16
JP6371350B2 (ja) 2018-08-08
EP3150610A1 (en) 2017-04-05
CY2018031I1 (el) 2019-11-27
SI2534153T2 (sl) 2024-07-31
EP2534153A1 (en) 2012-12-19
US20140243318A1 (en) 2014-08-28
LTPA2018517I1 (lt) 2018-12-10
US10278974B2 (en) 2019-05-07
JP6013551B2 (ja) 2016-10-25
CA3024216A1 (en) 2011-08-18
RU2012138892A (ru) 2014-03-20
CN104876937B (zh) 2017-07-28
SMT201900634T1 (it) 2020-01-14
RU2570198C2 (ru) 2015-12-10
FR18C1049I2 (fr) 2021-01-08

Similar Documents

Publication Publication Date Title
US10278974B2 (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
HK40091859A (en) Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
HK40022061A (en) Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
HK1234044A1 (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
HK1234044B (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
HK1176617B (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Legal Events

Date Code Title Description
AMND Amendment
PA0105 International application

Patent event date: 20120912

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170119

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170831

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170831

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170418

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160127

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120924

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120912

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180108

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20181128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180709

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180108

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20171129

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170831

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170418

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170119

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160127

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120924

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120912

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190227

PJ0201 Trial against decision of rejection

Patent event date: 20190227

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20181128

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20170831

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190405

Appeal identifier: 2019101000692

Request date: 20190227

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20190405

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2019101000692

Request date: 20190227

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20190405